Hematologic Malignancy
Diffuse Large B-Cell Lymphoma
CI-CAN-00005107DLBCLExplore in graph →
Hematologic355 active trials5 approved drugs19 evidence items
- NCIt
- C8851
- DOID
- 0050745
- Other
- 4 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005107DLBCLExplore in graph →
Clinical trials
1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04833114 | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)(Pola-R-ICE) | completed | Phase 3 | 306 | GWT-TUD GmbHOTHER | 4 | Jun 10, 2026 | clinicaltrials |
| NCT03274492 | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma(POLARIX) | completed | Phase 3 | 1,000 |
| Hoffmann-La RocheINDUSTRY |
| 22 |
| May 8, 2026 |
| clinicaltrials |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 | clinicaltrials |
| NCT04231448 | Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL(DEB) | completed | Phase 3 | 423 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03391466 | Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma(ZUMA-7) | completed | Phase 3 | 359 | Kite, A Gilead CompanyINDUSTRY | 14 | Dec 1, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT03263026 | Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ | completed | Phase 3 | 256 | Denovo Biopharma LLCINDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT04361279 | A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL | completed | Phase 3 | 421 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT02617485 | MabionCD20 Compared to MabThera in Lymphoma Patients(MADILYM) | completed | Phase 3 | 143 | Mabion SAINDUSTRY | 7 | Oct 25, 2023 | clinicaltrials |
| NCT01122472 | Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP(REMARC) | completed | Phase 3 | 650 | The Lymphoma Academic Research OrganisationOTHER | 9 | Jul 26, 2021 | clinicaltrials |
| NCT02128061 | Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ | completed | Phase 3 | 250 | The Lymphoma Academic Research OrganisationOTHER | 2 | Apr 13, 2021 | clinicaltrials |
| NCT03242902 | To Decrease Fatigue With Light Therapy(SPARKLE) | completed | Phase 3 | 166 | The Netherlands Cancer InstituteOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT02867566 | A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | completed | Phase 3 | 420 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01285765 | Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients | completed | Phase 3 | 650 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 14, 2020 | clinicaltrials |
| NCT01197560 | Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 / Phase 3 | 111 | CelgeneINDUSTRY | 9 | Nov 25, 2019 | clinicaltrials |
| NCT02268045 | Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma | completed | Phase 3 | 272 | mAbxience Research S.L.INDUSTRY | 12 | Sep 26, 2019 | clinicaltrials |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
| NCT00355199 | Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. | completed | Phase 3 | 246 | Gruppo Italiano Terapie Innovative nei LinfomiOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00790036 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy(PILLAR2) | completed | Phase 3 | 742 | Novartis PharmaceuticalsINDUSTRY | 34 | Jul 12, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT00400478 | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 | completed | Phase 3 | 683 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 26 | May 26, 2016 | clinicaltrials |
| NCT00002649 | Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 3 | 206 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT01459887 | Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma | completed | Phase 3 | 278 | Shanghai CP Guojian Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 26, 2011 | clinicaltrials |
| NCT01148446 | R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL(ANZINTER3) | completed | Phase 3 | 226 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 22, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Jun 10, 2026source: clinicaltrials